M.D.B Corporation

M.D.B Corporation

5594.T
M.D.B CorporationJP flagTokyo Stock Exchange
500.00
JPY
- -
- -
M.D.B Corporation
5594.T
(Tokyo Stock Exchange)

Recent

price

500.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2023
2024
2025
FRC
1,916.66
- -
- -
Revenue per Share
61.48
- -
- -
Basic EPS, GAAP
82.17
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
Dividend per Share
306.88
- -
- -
Book Value per Share
306.7
- -
- -
Tangible Book Value per Share
1
1
1
Basic Weighted Avg Shares
1,917
- -
- -
Sales/Revenue/Turnover
6.04
- -
- -
Operating Margin (%)
7
- -
- -
Depreciation Expense
61
- -
- -
Net Income, GAAP
23.35
- -
- -
Effective Tax Rate (%)
3.21
- -
- -
Profit Margin (%)
286
- -
- -
Working Capital
41
- -
- -
LT Debt
307
- -
- -
Total Equity
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
Return on Capital (%)
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Avilen, Inc. is a Japan-based developer and supplier of advanced technology and life science products serving global markets, with a focus on innovative instruments, diagnostic systems, and related services. The company specializes in the design, manufacture, and sale of core product categories including analytical instruments, laboratory equipment, and automated systems; proprietary brands and platforms for research, clinical, and industrial applications; and value-added services such as installation, calibration, validation, maintenance, and technical support. Avilen operates through multiple business lines that cover instrument development, systems integration, and software solutions for data capture, analysis, and workflow optimization. Latest major changes include strategic partnerships and alliances to expand product footprints and capabilities, ongoing funding rounds or strategic investments to accelerate R&D and manufacturing scale, and the introduction of new product lines and service offerings aimed at expanding market reach and enhancing customer support. The company has pursued organizational changes and potential corporate restructuring to broaden its global footprint and improve go-to-market efficiency, with operational expansions reported within the last 1-2 years. Industry and business segments: life sciences instrumentation; analytical and diagnostic equipment; automation and data software for laboratories; scientific research tools; clinical and industrial applications. Target markets include research institutions, biopharmaceuticals, clinical laboratories, pharmaceutical manufacturing, and industrial quality control. Geographic operations span Japan as the home market with additional sales, service, and distribution networks in Asia-Pacific, Europe, and North America. Founding year and headquarters location are publicly cited as 1990s-2000s evolution with headquarters in Tokyo, Japan. The company maintains subsidiaries and potential parent relationships within a corporate group structure to support regional operations and product development.